GLP-1 receptor activation enhances insulin secretion, suppresses appetite, and slows gastric emptying
Diabetes Care (2017) 40(11):155664
GLP-1 agonists are contraindicated in patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2
As the name suggests, this is positioned as an alternative to GLP-1 agonists, the popular new class of weight-loss drugs that now dominate the conversation around fat loss, transforming the $76 billion diet industry
Discuss Side Effects GLP-1s may cause side effects early on and throughout treatment
If youve been considering weight loss medications, youve probably come across terms like liraglutide, semaglutide , and GLP-1